<DOC>
	<DOCNO>NCT01257425</DOCNO>
	<brief_summary>The purpose study demonstrate pharmacodynamic equivalence triptorelin pamoate ( Pamorelin® LA 11.25 mg ) , apply either IM SC , term area curve [ AUC1-85day ] serum testosterone patient advanced prostate cancer .</brief_summary>
	<brief_title>Equivalence Intramuscular ( IM ) Versus Subcutaneous ( SC ) Applications Long Acting Pamorelin 11.25 mg</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Triptorelin Pamoate</mesh_term>
	<criteria>Histologically cytologically proven prostate cancer , locally advanced metastatic , rise PSA ( prostatespecific antigen ) fail local therapy , patient schedule receive androgen deprivation therapy Serum testosterone level ≥ 125 ng/dl ( 1.25 ng/ml , 1.25 microg/l , 4.3 nmol/l ) measure laboratory site within previous 6 month study start Karnofsky performance index &gt; 70 Expected survival ≥ 9 month Prior hormonal treatment prostate cancer include gonadotropinreleasing hormone ( GnRH ) agonists antagonist within last 12 month precede study concomitant treatment one substance ( ) Any current use within 6 month prior treatment start medication know affect metabolism and/or secretion androgenic hormone : ketoconazole , aminoglutethimide , oestrogens progesterone Patient risk spinal cord compression ureter obstruction Prior hypophysectomy adrenalectomy</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>